In Brief: MGI Pharma
Executive Summary
MGI Pharma: Decision Network Committee of the National Cancer Institute has voted in favor of funding and conducting human clinical trials of MGI 114, the lead analog among the company's acylfulvenes, MGI Pharma announces July 25. A clinical trials agreement between NCI and the company has not yet been completed. MGI Pharma states that the NCI trial would complement ongoing Phase I research of MGI 114 in cancer patients, which the company initiated in December...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth